Genes encoding subunits of SWI/SNF (BAF) chromatinremodeling complexes are collectively mutated in ~20% of all human cancers 1,2 . Although ARID1A is the most frequent target of mutations, the mechanism by which its inactivation promotes tumorigenesis is unclear. Here we demonstrate that Arid1a functions as a tumor suppressor in the mouse colon, but not the small intestine, and that invasive ARID1A-deficient adenocarcinomas resemble human colorectal cancer (CRC). These tumors lack deregulation of APC/b-catenin signaling components, which are crucial gatekeepers in common forms of intestinal cancer. We find that ARID1A normally targets SWI/SNF complexes to enhancers, where they function in coordination with transcription factors to facilitate gene activation. ARID1B preserves SWI/SNF function in ARID1Adeficient cells, but defects in SWI/SNF targeting and control of enhancer activity cause extensive dysregulation of gene expression. These findings represent an advance in colon cancer modeling and implicate enhancer-mediated gene regulation as a principal tumor-suppressor function of ARID1A.
Genes encoding subunits of SWI/SNF (BAF) chromatinremodeling complexes are collectively mutated in ~20% of all human cancers 1,2 . Although ARID1A is the most frequent target of mutations, the mechanism by which its inactivation promotes tumorigenesis is unclear. Here we demonstrate that Arid1a functions as a tumor suppressor in the mouse colon, but not the small intestine, and that invasive ARID1A-deficient adenocarcinomas resemble human colorectal cancer (CRC). These tumors lack deregulation of APC/b-catenin signaling components, which are crucial gatekeepers in common forms of intestinal cancer. We find that ARID1A normally targets SWI/SNF complexes to enhancers, where they function in coordination with transcription factors to facilitate gene activation. ARID1B preserves SWI/SNF function in ARID1Adeficient cells, but defects in SWI/SNF targeting and control of enhancer activity cause extensive dysregulation of gene expression. These findings represent an advance in colon cancer modeling and implicate enhancer-mediated gene regulation as a principal tumor-suppressor function of ARID1A.
As inactivating ARID1A mutations occur in a broad spectrum of human cancers 2 , we used a mouse model to identify tissues where ARID1A might function as a tumor suppressor in vivo. We generated Mx1-Cre; Arid1a fl/fl mice to achieve sporadic, interferonresponsive inactivation of both Arid1a alleles across many tissues 3 ( Supplementary Fig. 1a,b) . Mice were initially healthy after induction of Cre activity with the synthetic immunostimulant polyinosinic:polycytidylic acid (poly(I:C)), but they required euthanasia at a median of 296 d owing to emaciation and rectal prolapse ( Fig. 1a and Supplementary Fig. 1c ). We identified nodular and polypoid tumors in the colons of these mice, often at multiple non-contiguous sites, but never in the small intestine ( Fig. 1b) . Tumor histology was consistent with invasive colon adenocarcinoma (Fig. 1c) , a malignant neoplasm derived from glandular colonic epithelium 4 . ARID1A expression was lost in <10% of normal colon epithelial cells, but was absent in all tumor cells ( Fig. 1d) . Vil1-CreER T2 ; Arid1a fl/fl mice, in which Arid1a inactivation is restricted to intestinal epithelial cells 5 , also developed invasive ARID1A-deficient adenocarcinoma ( Supplementary Fig. 2a-d) ; tumor formation thus reflects epithelial cell-intrinsic ARID1A deficiency. Tumors in Arid1a fl/fl mice were marked by prominent mucinous differentiation and the presence of tumor-infiltrating lymphocytes (Fig. 1e,f and Supplementary  Fig. 2e-g) , features associated particularly with human CRCs that exhibit microsatellite instability (MSI) 6 . As ARID1A is the third most significantly mutated gene in human CRC, with the highest frequency of mutations (~39%) in cancers of the MSI type 7, 8 , these findings are highly relevant to human disease.
To identify potential cooperating events in tumorigenesis driven by ARID1A deficiency, we obtained whole-exome sequences for DNA isolated from tumor and matched normal tissue from three Mx1-Cre; Arid1a fl/fl mice. Variant analysis of the exome data identified few nonsynonymous mutations, none of which were in genes recurrently mutated in human CRC 7 (Supplementary Fig. 3 and Supplementary  Table 1 ). APC inactivation is an initiating event in human CRC, which drives adenoma formation by allowing β-catenin to translocate to the nucleus and trigger constitutive transcription of Wnt target genes 9, 10 . In Arid1a fl/fl tumors, β-catenin was localized exclusively at the plasma membrane, indicating that APC function is intact ( Fig. 2a) . To characterize further the relationship between ARID1A and APC inactivation in colon tumorigenesis, we obtained mice carrying the germline Apc Min mutation 11 and generated Apc Min ; Arid1a −/− (Apc Min ; Vil1-CreER T2 ; Arid1a fl/fl ) mice ( Supplementary Fig. 4a,b) . Whereas Apc Min mice developed the expected number of adenomas throughout the intestines, Apc Min ; Arid1a −/− mice had significantly fewer intestinal tumors ( Fig. 2b and Supplementary Fig. 4c ). The few tumors that did arise in Apc Min ; Arid1a −/− mice were non-invasive adenomas that were histologically similar to those in Apc Min mice; these tumors retained ARID1A expression and exhibited nuclear β-catenin localization (Fig. 2c,d and Supplementary Fig. 4d,e ). Thus, ARID1A loss drives invasive colon cancer via a mechanism independent of APC inactivation; further, ARID1A is required to facilitate tumorigenesis driven by inactivation of APC.
ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice
To investigate the tumor-suppressor function of ARID1A, we used the HCT116 MSI + human CRC cell line and isogenic lines with monoallelic (ARID1A +/− ) or biallelic (ARID1A −/− ) deletion of ARID1A. Parental cells with wild-type ARID1A grew in clustered colonies with tight cell-cell adhesion, whereas ARID1A −/− cells spread across the culture dish with elongated, spindle-shaped morphologies and frequent filopodia ( Fig. 3a) . ARID1A −/− cells proliferated normally ( Fig. 3b ) but exhibited increased invasiveness ( Fig. 3c ) and reduced expression of the cell adhesion protein E-cadherin ( Fig. 3d) ; we did not identify a molecular signature associated with epithelialmesenchymal transition (EMT) ( Fig. 3e and Supplementary Fig. 5 ). Notably, ARID1A depletion causes similar defects in cells derived from human gastric and hepatocellular carcinomas, which also frequently carry inactivating ARID1A mutations 12, 13 .
ARID1A is mutually exclusive in SWI/SNF complexes with ARID1B; both proteins have DNA-binding activity and are implicated in targeting SWI/SNF complexes to chromatin 14 . To examine the consequences of ARID1A loss on SWI/SNF targeting, we performed ChIP-seq for two core subunits-SMARCA4 (BRG1) and SMARCC1 (BAF155)-in wildtype and ARID1A −/− HCT116 cells. SMARCA4 and SMARCC1 binding were highly correlated ( Supplementary Fig. 6 ), and we considered sites enriched for both subunits to be SWI/SNF binding sites (Online Methods and Supplementary Table 2 ). A large majority of SWI/SNF binding sites (79.2%) showed loss of SMARCA4 and SMARCC1 occupancy in ARID1A −/− cells ( Fig. 3f) . Independent ChIP-qPCR experiments showed that ARID1A was present at these sites in wild-type cells, consistent with a direct role for this subunit in SWI/SNF targeting ( Supplementary Fig. 7 and Supplementary Table 3 ). Few sites gained SMARCA4 and SMARCC1 binding in ARID1A −/− cells (1.5%; Fig. 3f) ; however, sites that did also gained ARID1B binding ( Supplementary  Fig. 7 and Supplementary Table 3 ). Immunoprecipitation confirmed that ARID1B-containing SWI/SNF complexes were intact in ARID1A −/− cells ( Fig. 3g) . Proliferation of these cells was impaired by ARID1B knockdown (Fig. 3h,i) . Thus, ARID1A deficiency alters SWI/SNF targeting to genomic sites, while residual SWI/SNF activity is preserved through ARID1B. Notably, ARID1B is a synthetic lethal vulnerability in ARID1A-mutant human cancer 15, 16 ; cells in Arid1a fl/fl tumors also retain expression of ARID1B ( Supplementary Fig. 8 ).
To study the consequences of altered SWI/SNF targeting in ARID1A −/− cells, we characterized histone modifications associated l e t t e r s l e t t e r s with active cis-regulatory elements 17 (H3K4me3, H3K4me1, and H3K27ac) at SWI/SNF binding sites in wild-type and ARID1A −/− HCT116 cells. Under both conditions, SWI/SNF binding was highly enriched at active enhancers marked with H3K4me1 and H3K27ac ( Fig. 4a) ; in contrast, SWI/SNF binding was limited at active promoters, defined as transcription start site (TSS)-overlapping regions enriched for H3K4me3 (Online Methods and Supplementary Fig. 9 ). Of note, in TSS-distal regions, H3K27ac signal was diminished in ARID1A −/− cells at sites that lost SWI/SNF binding and was dramatically increased at the few sites where SWI/SNF binding was gained ( Fig. 4b) . Genome-wide examination identified widespread changes in H3K27ac levels at enhancers, whereas promoters showed little change ( Fig. 4c) . Because H3K27ac distinguishes active from poised and inactive enhancers 17, 18 , we asked whether altered SWI/SNF targeting in ARID1A −/− cells affected enhancer activity. Indeed, changes in SWI/SNF binding at TSS-distal sites correlated with changes in mRNA levels of the nearest genes, as quantified by RNA-seq ( Fig. 4d and Supplementary Table 4 ). Partial ARID1A deficiency also affected enhancer activity, with ARID1A +/− cells exhibiting intermediate changes in H3K27ac levels at enhancers and in transcription of the nearest genes ( Supplementary Fig. 10 ). SWI/SNF complexes are capable of mobilizing nucleosomes 19, 20 , and, indeed, ARID1A loss changed not only the levels of histone modifications at enhancers but also their locations ( Fig. 4b,e ). Together, these findings indicate that ARID1A deficiency specifically impairs enhancer configuration and activity, with marked consequences for gene expression.
To determine whether control of enhancer activity by SWI/SNF complexes is coordinated with transcription factors, we analyzed sequence motifs at enhancers sensitive to ARID1A loss. The CTCF motif was relatively depleted in regions of H3K27ac loss, implying that CTCF-bound insulator regions may resist modulation, whereas the AP-1 (JUND/FOSL1) motif was most enriched ( Fig. 5a and Supplementary Table 5 ). ChIP-seq profiles for HCT116 cells, including those generated by ENCODE 21 (Encyclopedia of DNA Elements; Supplementary Table 6 ), further showed that H3K27ac loss was most strongly associated with sites bound in wild-type cells by SWI/SNF l e t t e r s complexes and/or transcription factors including AP-1, CEBPβ, and TEAD4 ( Fig. 5b) . Among the factors assessed in HCT116 cells, binding of these transcription factors correlated most strongly with SWI/SNF occupancy (Supplementary Fig. 6b ) and was higher at enhancers that lost activity than at enhancers that were unaffected by ARID1A deficiency (Fig. 5c ). Gene Ontology (GO) analysis of the nearest genes implicated enhancers that lost activity as regulators of cell adhesion, development, differentiation, and morphogenesis ( Supplementary  Fig. 11a and Supplementary Table 5 ). The activity of super-enhancers, key regulators of genes that confer cell identity 22 , was also affected ( Supplementary Fig. 12 and Supplementary Table 5 ). These results establish a broad role for ARID1A in regulating active enhancers in HCT116 cells, converging on dominant transcription factors that provide a large fraction of tissue-specific gene regulation.
To determine whether ARID1A loss impairs enhancer activity in vivo, we examined H3K27ac and gene expression in the colonic epithelium of wild-type and Vil1-CreER T2 ; Arid1a fl/fl mice. Again, whereas promoter activation states showed little change with ARID1A loss (Fig. 5d) , the effects on H3K27ac levels at enhancers were significant and were correlated with changes in the mRNA levels of the nearest genes ( Fig. 5e) . Developmental enhancers were identified as being most sensitive to ARID1A loss, exhibiting enrichment for many GO terms shared with enhancers that exhibited altered activity after ARID1A loss in HCT116 cells ( Supplementary Fig. 11b and Supplementary Table 7 ). More than 1,000 genes were dysregulated >2-fold in Arid1a −/− colonic epithelium (false discovery rate (FDR) < 0.05), including several genes known to be associated with cancer ( Fig. 5f and Supplementary Table  8 ). For example, the Gasdermins, established tumor suppressors in gastric epithelium 23, 24 , were markedly downregulated ( Fig. 5g,h) . Although it is difficult to attribute tumorigenesis to discrete target genes, our findings implicate broad control of enhancer activity as the SWI/SNF function crucially impaired in ARID1A-deficient cancers. WT ARID1A Fold change in invasion 
l e t t e r s
Despite the characterization of APC as a gatekeeper in human CRC 9,10 , normal patterns of β-catenin staining have long been observed in tumors with MSI 25 . Indeed, recent molecular classification showed that APC mutations occur with relatively low frequency in the subtype of human CRC (consensus molecular subtype CMS 1: MSI, immune) enriched for mutations in ARID1A 26 . Notably, not only are tumors in Arid1a fl/fl mice histologically distinct from those that develop with APC inactivation, but they also reflect with greater accuracy the features of human CRC-aggressive local tissue invasion, long latency, and exclusive origin in the colon-that are absent in current models 11 . Arid1a fl/fl mice thus establish a new pathway to colon tumorigenesis and provide a sound model for further investigation of cell-intrinsic and cell-extrinsic factors that might contribute to colon tumor formation, progression to invasive cancer, and response to therapy.
Although SWI/SNF function is described at both promoters and enhancers [27] [28] [29] , our findings implicate enhancers as the principal sites at which SWI/SNF complexes function to regulate gene activation. When ARID1A is absent, SWI/SNF is lost from thousands of enhancers that subsequently lose activity-showing reduced H3K27ac levels and expression of nearest genes-while residual SWI/SNF complexes containing ARID1B bind enhancers that remain active ( Fig. 6) . Enhancers are major determinants of cell type specificity in gene expression 30 ; ARID1A loss impairs SWI/SNF control of enhancers bound by dominant transcription factors that activate gene expression programs critical for development and differentiation. As SWI/SNF H3K4me1  H3K4me1  H3K27ac  SRF  MAX  RAD21  SIN3A  REST  USF1  ZBTB33  YY1  ELF1  EGR1  TCF7L2  CTCF  ZNF274  H3K9me3  H3K4me3  H3K4me3  H3K36me3  POLR2A  SP1  ATF3  CBX3  CEBPβ  TEAD4 CTCF P = 8.6 × 10 complexes regulate gene expression across lineages and developmental states 31, 32 , defective SWI/SNF control of enhancer activity may underlie not only the oncogenic drive of ARID1A-mutant CRC but also that of other human malignancies driven by alterations in ARID1A and other SWI/SNF subunits.
oNLINe MeTHoDS
Mouse experiments. All experiments were performed with strict adherence to our Institutional Animal Care and Use Committee (IACUC)-approved Animal Experimentation Protocol 12-017 and guidelines of the Dana-Farber Animal Resource Facility (ARF). Mx1-Cre; Arid1a fl/fl mice. Mx1-Cre mice purchased from Jackson Labs (stock 003556) were bred to Arid1a fl/fl mice obtained from Z. Wang (University of Michigan Medical School) 33 . Six-to 8-week-old Mx1-Cre; Arid1a fl/fl and littermate control Arid1a fl/fl mice were administered pI-pC (polyinosinic-polycytidylic acid, Invivogen tlrl-pic) via intraperitoneal injection at 25 µg/g every other day for 7 d. Excision of Arid1a was evaluated in mice 1 week after injection by PCR of DNA collected from mouse tissues using primers on each side of the loxP-flanked exon (Supplementary Fig. 1a,b) . Mice were monitored for health and euthanized upon instruction by the ARF veterinarian staff. Whole-mouse necroscopies were conducted on the first cohort of mice at the Dana-Farber/Harvard Cancer Center Rodent Pathology Core. Sample size for survival analysis was calculated using estimated effect size from this cohort of mice; no animals were excluded. Formalin-fixed intestines were processed for histology and immunohistochemistry at the Dana-Farber Cancer Institute Specialized Histopathology Core.
Vil1-CreER T2 ; Arid1a fl/fl mice. Five-to 7-week-old Vil1-CreER T2 ; Arid1a fl/fl mice and littermate control Arid1a fl/fl mice were administered 1 mg of tamoxifen (T5648, Sigma) dissolved in sunflower oil (S5007, Sigma) via intraperitoneal injection for five consecutive days. Three Vil1-CreER T2 ; Arid1a fl/fl mice and three control Arid1a fl/fl mice were euthanized 8 weeks after injection for dissociation of colon epithelial cells 34 . Specifically, mouse colons were dissected, flushed, and splayed. Colon pieces were rinsed in PBS, incubated in 5 mM EDTA, and shaken for 2 min to release dissociated epithelial cells. Additional mice were aged for tumor analysis. Intestines were fixed in formalin and processed for histology and immunohistochemistry at the Dana-Farber Cancer Institute Specialized Histopathology Core.
Apc Min and Apc Min ; Arid1a −/− mice. Apc Min mice purchased from Jackson Labs (C57BL/6J-Apc-min/J; stock 002020) were bred to Vil1-CreER T2 ; Arid1a fl/fl mice to generate Apc Min ; Vil1-CreER T2 ; Arid1a fl/fl (Apc Min ; Arid1a −/− ) mice and littermate control Apc Min ; Arid1a fl/fl (Apc Min ) mice. Mice aged 5-6 weeks were injected intraperitoneally with 1 mg of tamoxifen (T5648, Sigma) dissolved in sunflower oil (S5007, Sigma) for five consecutive days. Age-matched Apc Min and Apc Min ; Arid1a −/− mice were euthanized at 5-6 months. Genotype-blinded counts of intestinal tumors were obtained under a dissecting microscope. A two-tailed t test was used to evaluate statistical significance, and an F test was used to compare variances. Intestines were fixed in formalin and processed for histology and immunohistochemistry at the Dana-Farber Cancer Institute Specialized Histopathology Core.
Whole-exome sequencing. DNA from flash-frozen matched tumor and tail tissue from Mx1-Cre; Arid1a fl/fl mice was purified with the DNeasy Blood and Tissue kit (Qiagen, 69504) following histological confirmation of invasive adenocarcinoma. Samples were further processed and analyzed at the Dana-Farber Center for Cancer Computational Biology (CCCB). Target enrichment was performed using the SureSelect XT Mouse All Exon (Agilent Technologies) bait library. Samples were sequenced on the Next-Seq500 (Illumina) system using the PE-150 flow cell. Following sequencing and demultiplexing, sequencing reads were trimmed such that the lowest quartile of the Phred-scaled Q score was greater than 28; typical read lengths were approximately 140 bp. The paired reads were aligned to the Ensembl GRCm38.75 genome using BWA-mem 35, 36 with default parameters. Following initial alignment, reads were further processed using GATK best-practices for whole-exome sequencing data, including marking of duplicates, de novo realignment near putative indels, and base quality score recalibration.
Variant calling was performed with VarScan2 software 37 (v2.4.1), owing to the paired (tumor-normal) design of the experiment. Somatic, germline, and loss-of-heterozygosity events are reported. Default parameters were used, requiring a minimum coverage depth of eight reads for variant calls. In addition to the set of VarScan2 calls, MuTect software 38 was used to generate a second set of somatic point mutations.
VarScan2 was also used to detect putative copy number variations (CNVs) between the matched samples. Following the recommendation of the documentation, CNV calls were filtered and finely smoothed/segmented using the Bioconductor DNACopy package, which implements the CBS algorithm. Additionally, a second set of CNV calls was generated using CONTRA software 39 with default parameters and specifying the targeted regions from the exome capture process. reversed, and samples were treated with proteinase K and RNase A. ChIP DNA was extracted with the MinElute PCR purification kit (Qiagen) and quantified with the Quant-iT PicoGreen dsDNA Assay kit (Life Technologies). 10 ng of purified ChIP DNA was used to prepare sequencing libraries for the Illumina HiSeq Genome Analyzer. ChIP-qPCR was performed on the ViiA7 Real-Time PCR System (Life Technologies) using SYBR Select Master Mix (Life Technologies) with 1 µl of purified ChIP DNA in duplicate in 384-well format. A minimum of two independent replicate experiments were performed for each factor analyzed by ChIP-qPCR.
Dissociated colon epithelial cells pooled from three Vil1-CreER T2 ; Arid1a fl/fl mice and from three control Arid1a fl/fl mice were fixed in 2% formaldehyde, lysed, and pulsed at 15% amplitude on a tip-sonicator. Sonicated chromatin was immunoprecipitated using antibodies for H3K27ac (Abcam, ab4729) and H3K4me3 (Abcam, ab8580). Antibody:chromatin complexes were pulled down with Protein G Dynabeads (Life Technologies, 10004D), washed, and eluted. Chromatin cross-links were reversed, and samples were treated with proteinase K and RNase A. ChIP DNA was extracted with the MinElute PCR purification kit (Qiagen) and quantified with the Quant-iT PicoGreen dsDNA Assay kit (Life Technologies). 10 ng of purified ChIP DNA was used to prepare sequencing libraries for the Illumina HiSeq Genome Analyzer.
Sample preparation for RNA-seq. TRIzol Reagent (Life Technologies, 15596-026) was used to isolate RNA from collected HCT116 isogenic cell lines and dissociated mouse colon epithelial cells. RNA was further purified with the RNeasy Mini kit (Qiagen) and Turbo DNA-Free kit (Ambion; mouse cells only). Sequencing libraries were generated using TruSeq technology (Illumina) for the Illumina HiSeq Genome Analyzer.
ChIP-qPCR processing. ChIP-qPCR signals were normalized using the percent input method: (100 × 2^(adjusted input − C t (IP)). For each independent replicate experiment, statistical significance in wild-type versus ARID1A −/− ChIP-qPCR signal was determined using the Holm-Sidak method, with α = 5.000% (GraphPad Prism version 6 for Mac OS X). Computations assume that all rows (individual ChIP-qPCR sites) are sampled from populations with the same scatter (s.d.).
Log-transformed fold change for each independent replicate experiment was calculated using the ratio of the percent input for ARID1A −/− over wild type (averaged over technical replicates). Averages of ARID1A −/− /wild-type log-transformed fold change values were calculated for each factor from all independent replicate experiments for Supplementary Figure 7b,c. ChIP-seq processing. Alignment, fragment size estimation, and library complexity. The sequenced reads were aligned to the hg19 or mm9 genome assembly using Bowtie 40 0.12.6, allowing up to ten matches ('-m 10--best' options). For HCT116, reads on the 24 assembled chromosomes excluding the ENCODE blacklisted regions were kept for downstream analysis. For the mouse samples, reads on the 19 assembled autosomes excluding a custom 280-kb blacklist region were kept for downstream analysis. The custom blacklist regions were selected on the basis of very high signal in input tracks in a parallel study (GSE71509). Peaks of cross-correlation profiles were identified to estimate the typical fragment size for each sample. The typical fragment size for the different samples ranged between 140 and 180 bp. Each read was considered to represent a signal at half typical fragment size from the 5′ end. Library complexity was calculated for each sample as the number of unique base-pair positions mapped onto each strand divided by the total number of mapped reads. For batches of experiments where the typical library complexity was below 90% (all mouse samples, HCT116 H3K4me1, H3K4me3 and matching input), only one read mapping to each position was kept.
Identification of regions of enrichment. Different ChIP-seq regions of enrichment (RoEs) were identified using the SPP package 41 in R, with the function get.broad.enrichment.clusters and option window.size = 500, with matching input samples for each immunoprecipitation experiment, using appropriate z.thr values for each analysis as specified below. The input samples for samples for wild-type and ARID1A-deficient mice had relatively low sequencing depth (5.7 and 12.0 million reads after selecting one read per position). The two samples appeared to show no more systematic variability than expected from the statistical variability due to low sequencing depth. Therefore, the two were merged, and the combined input was provided to SPP as a control for both wild-type and ARID1A-deficient H3K27ac ChIP-seq.
Defining active TSSs and H3K4me3 regions of enrichment. Active TSSs in HCT116 cells were defined as all TSSs in Ensembl release GRCh37.72 that overlapped H3K4me3 RoEs (z > 4) in either condition. Active TSSs in mouse colon were defined as all TSSs in Ensembl release NCBIM37.67 that overlapped an H3K27ac (z > 4) peak in either condition (H3K4me3 ChIP-seq failed for ARID1A-deficient mouse colon; the enrichment at TSSs was relatively low for the wild-type colon sample). Additionally, H3K4me3 RoEs in mouse colon were defined as the union of RoEs (z > 4) called with the wildtype colon sample and a wild-type MEF sample from the accompanying study (GSE71509). These two regions, that is, 'active TSSs' and 'H3K4me3 RoEs' were used together to conservatively define TSS-proximal and TSS-distal regions in downstream analyses, as specified below.
Identification and classification of SWI/SNF binding sites. SWI/SNF binding sites were identified in two steps. First, overlapping SMARCA4 and SMARCC1 RoEs with z > 4 were called for each condition, wild type and ARID1A −/− . Next, the union of the regions for the two conditions was calculated. This approach reduces any bias that may arise in differential RoE calling due to thresholds. The sites that were called in wild type or those where the signal in wild type was more than half the signal in ARID1A −/− were considered as SWI/SNF binding sites in wild-type cells; the complementary selection was performed for SWI/SNF binding sites in ARID1A −/− cells (used in Fig. 4a ). SWI/SNF binding sites overlapping both an active TSS and an H3K4me3 RoE were called TSS proximal. Those more than 1 kb away from an H3K4me3 RoE and more than 2 kb away from an active TSS were called TSS distal. Others were ambiguous and excluded from studies specific to TSS-proximal or TSS-distal sites. When we evaluated where SWI/SNF binding falls in the genome, we used H3K27ac and H3K4me1 RoEs that were called inclusively with a threshold of z > 3. Changes in TSS-distal SWI/SNF binding upon ARID1A loss were evaluated at each binding site by dividing the library-size-normalized immunoprecipitation signal for SMARCA4 and SMARCC1 in ARID1A −/− cells by the wild-type signal. If the geometric mean of change was greater than 1.5-fold and both factors showed increased signal, the RoE was called as gained/strengthened. In reverse, if the geometric mean of change was less than 2/3-fold and both factors showed decreased signal, the RoE was called as lost/weakened. Other sites were called as unchanged (see colors in Fig. 3f) .
Identification and classification of H3K27ac RoEs (promoters and enhancers). H3K27ac RoEs with z > 4 were called specifically to study changes in this mark in HCT116 and colon epithelial cells ( Figs. 4c and 5e ). Similar to SWI/SNF binding sites, H3K27ac RoEs from different conditions were merged; ones overlapping both an active TSS and an H3K4me3 RoE were defined as promoters, and ones that were more than 1 kb away from an H3K4me3 RoE and more than 2 kb away from an active TSS were called as enhancers.
Gene ontology analysis for enhancers. To identify enhancers that lost SWI/SNF binding, we used an inclusive definition of SWI/SNF binding as overlapping SMARCA4 and SMARCC1 RoEs with a threshold of z > 3. Enhancers with SWI/SNF binding, where the average SMARCA4 and SMARCC1 signal was down more than 1.5-fold, were called as SWI/SNF losing enhancers. GO analysis for these SWI/SNF losing enhancers was performed as follows: GO databases were downloaded from http://geneontology.org/ on 29 April 2014. Each enhancer was associated to the closest active TSS within 100 kb. P values for gene set enrichment for genes associated with SWI/SNF losing enhancers were calculated relative to genes associated with any enhancer using hypergeometric tests. q values were obtained on the basis of the Benjamini-Hochberg procedure.
Immunoprecipitation efficiency correction for H3K27ac samples. The efficacy of immunoprecipitation pulldown may vary between different ChIP-seq experiments. A number of lines of evidence suggested that the real levels of H3K27ac are unchanged at a large fraction of promoters upon ARID1A deletion: (i) we found that a large fraction of promoters show the same amount of fold change with very small variance; (ii) the typical fold change was independent of SWI/SNF binding at promoters and was the same as at enhancers with no SWI/SNF binding; and (iii) in the accompanying MEF study, we observed different fold changes at promoters, both greater and less than one-fold, for replicates of experiments upon Smarcb1 knockout, while we saw consistent decrease of H3K27ac levels in immunoblots and at enhancers. On the basis of these observations, we applied a small multiplicative factor on H3K27ac samples to set the mode of the log-transformed fold change distribution at promoters to zero while comparing wild-type and ARID1A-deficient samples. These factors were as follows: HCT116 (parental, 0.95; ARID1A −/− , 1.31; ARID1A +/− , 0.82) and mouse colon epithelial cells (wild type, 1.08; ARID1A deficient, 0.92). This normalization procedure does not affect the qualitative observations presented. We refrained from applying a similar normalization for other ChIP-seq sample pairs, as we could not confidently determine a set of regions where they were unaffected upon ARID1A loss.
ChIP-seq visualization. Genomic profiles for visualization were generated using Gaussian smoothing with σ = 100 bp after library size normalization (for example, in Fig. 4e, or output wig files) . The SWI/SNF binding site heat maps (for example, in Fig. 4b) were centered at the position with the highest signal in the smoothed profile obtained by summing the four tracks considered (wild type or ARID1A −/− , SMARCA4, and SMARCC1). The heat maps show input-subtracted values, whereas the browser shots show raw smoothed signal. The average profiles for each class in Figure 4b (for example, unchanged) were obtained as the 0.1-0.9 trimmed linear mean at each position.
Identification of super-enhancers. Super-enhancers were called with a slightly modified approach from the original method 22 . H3K27ac RoEs were called as described above. We did not remove TSS-proximal peaks but stitched together all RoEs within 12.5 kb. For each stitched RoE, immunoprecipitation and input signals were calculated only in portions that did not intersect H3K4me3 RoEs (as defined above). We found this approach to be better at removing false positives from stitched enhancer peaks that encompassed active TSSs. Each super-enhancer was associated with the closest active TSS, as defined above, within 300 kb. If more than one gene was similarly close to a super-enhancer (at most 50 kb further than the closest gene), those genes are also listed in the super-enhancer-associated gene list. The inclusive threshold of z > 3 was used to identify SWI/SNF binding sites within super-enhancers in Supplementary Figure 12c .
Transcription factor motif enrichment. Transcription factor motif maps for hg19 for 4,095 motifs (including a redundant set of real transcription factor recognition elements and shuffled motif control sequences) were downloaded (http://compbio.mit.edu/encode-motifs/) 42 . The position weight matrix (PWM) for each motif was calculated on the basis of the actual sequences of the provided motif locations. The number of motif occurrences was counted for each motif inside lost/weakened enhancers (H3K27ac fold change < 1/1.5) and unchanged enhancers (1/1.5 < H3K27ac fold change < 1.5). A Lowess curve was calculated to model the ratio of counts for each motif (sensitive/insensitive) as a function of the GC content of the motif PWM. This curve was used to calculate back the null hypothesis expected number of occurrences for each motif in the lost/weakened. Figure 5a shows observed counts versus expected counts for the 4,095 motifs. PWMs for two selected motifs (' AP-1_known3_8mer' and 'CTCF_known1_8mer') are displayed in the figure. Motif similarity was assessed on the basis of Pearson correlation values between motif PWMs; motifs that are similar to the two selected motifs (r > 0.85) are highlighted in the figure.
Correlation of binding of different factors in wild-type cells with changes in H3K27ac levels. ChIP-seq signal around the peak point of each H3K27ac RoE was calculated within ±1.5 kb, per million mapped reads; a pseudocount of 1 was added, and the values were logged (L = log 2 (1 + signal)). The change in H3K27ac levels was calculated using samples generated in this work as L(ARID1A) − L(wild type). For each factor from the ENCODE Project, the L values were averaged over replicates at each H3K27ac RoE. The Pearson's correlation between each factor and the change in H3K27ac levels is plotted (Fig. 5b) .
RNA-seq processing. The sequenced reads from each sample were aligned to the human or mouse genome + transcriptome assemblies (GRCh37.72 or NCBIM37.67) using TopHat 43 v2.0.8 with default parameters except turning off novel junction search ('-G <gtf>--no-novel-juncs' options). The transcriptome was self-merged to allow processing with the Cufflinks 44 v2.1.1 tool cuffdiff, 'cuffcompare -s hg19.fa -CG -r GRCh37.72.gtf GRCh37.72.gtf ' (and similarly for mouse). Different conditions were compared using cuffdiff with default parameters and bias correction ('-G <gtf> -b' options).
Each SWI/SNF or H3K27ac RoE was associated with the closest active TSS as defined above. The connection between change in ChIP-seq signal and RNA-seq change (Figs. 4d and 5f) was studied for TSS-distal RoEs. Only RoEs for which the closest active TSS was between 5 kb and 100 kb away were retained. Immunoprecipitation signal was quantified as 'total IP signal in RoE per billion mapped reads + pseudocount of 0.1' . RNA signal was quantified as 'normalized gene level count value from cuffdiff + 5' . The ratio of immunoprecipitation signal for ARID1A deficient divided by wild type was used to categorize RoEs into four groups: more than 3-fold signal loss, between 1.5-and 3-fold signal loss, less than 1.5-fold change, and greater than 1.5-fold signal increase. The ratio of RNA-seq signal for ARID1A-deficient divided by wild-type signal was plotted for each category (Figs. 4d and 5e) .
The heat maps for RNA-seq results show mean-shifted log-transformed expression values: log 2 (normalized gene level count value from cuffdiff + 5) − log 2 (average value for the gene across all samples).
